Page 24 - 南京医科大学自然版

第44卷第7期
·908 · 南 京 医 科 大 学 学 报 2024年7月

（7）：990-998 tions［J］. Rev Med Virol，2021，31（2）：e2163
［12］HEIDARY M，EBRAHIMI SAMANGANI A，KARGARI ［24］BARKS J D E，LIU Y Q，DOPP I A，et al. Azithromycin
A，et al. Mechanism of action，resistance，synergism，and reduces inflammation ⁃ amplified hypoxic ⁃ ischemic brain
clinical implications of azithromycin［J］. J Clin Lab Anal， injury in neonatal rats［J］. Pediatr Res，2022，92（2）：
2022，36（6）：e24427 415-423
［13］RAZAK A，ALSHEHRI N. Azithromycin for preventing ［25］HAFNER M，PAUKNER S，WICHA W W，et al. Anti⁃
bronchopulmonary dysplasia in preterm infants：a system⁃ inflammatory activity of lefamulin versus azithromycin
atic review and meta ⁃ analysis［J］. Pediatr Pulmonol， and dexamethasone in vivo and in vitro in a lipopolysac⁃
2021，56（5）：957-966 charide⁃induced lung neutrophilia mouse model［J］. PLoS
［14］ CHEN X Y，HAN D S，WANG X，et al. Vascular and One，2021，16（9）：e0237659
pulmonary effects of ibuprofen on neonatal lung develop⁃ ［26］TARIQUE A A，TULADHAR N，KELK D，et al. Azithro⁃
ment［J］. Respir Res，2023，24（1）：39 mycin augments bacterial uptake and anti ⁃ inflammatory
［15］HUANG Z L，LIN B C，HAN D S，et al. Platelets are indis⁃ macrophage polarization in cystic fibrosis［J］. Cells，
pensable for alveolar development in neonatal mice［J］. 2024，13（2）：166
Front Pediatr，2022，10：943054 ［27］ CRAMER C L，PATTERSON A，ALCHAKAKI A，et al.
［16］ SAHNI M ，BHANDARI V. Patho⁃mechanisms of the Immunomodulatory indications of azithromycin in respira⁃
origins of bronchopulmonary dysplasia［J］. Mol Cell Pedi⁃ tory disease：a concise review for the clinician［J］. Post⁃
atr，2021，8（1）：21 grad Med，2017，129（5）：493-499
［17］GIUSTO K，WANCZYK H，JENSEN T，et al. Hyperoxia⁃ ［28］PŁUSA T. Azithromycin in the treatment of patients with
induced bronchopulmonary dysplasia：better models for exacerbation of chronic obstructive pulmonary disease［J］.
better therapies［J］. Dis Model Mech，2021，14（2）： Pol Merkur Lekarski，2020，48（283）：65-68
dmm047753 ［29］ ECHEVERRÍA ⁃ ESNAL D，MARTIN ⁃ ONTIYUELO C，
［18］ SHAHZAD T，CHAO C M，HADZIC S，et al. TRAIL NAVARRETE⁃ROUCO M E，et al. Azithromycin in the
protects the immature lung from hyperoxic injury［J］. treatment of COVID⁃19：a review［J］. Expert Rev Anti
Cell Death Dis，2022，13（7）：614 Infect Ther，2021，19（2）：147-163
［19］WAGENAAR G T，TER HORST S A，VAN GASTELEN ［30］NUNES C R，PROCIANOY R S，CORSO A L，et al. Use
M A，et al. Gene expression profile and histopathology of of azithromycin for the prevention of lung injury in
experimental bronchopulmonary dysplasia induced by mechanically ventilated preterm neonates：arandomized
prolonged oxidative stress［J］. Free Radic Biol Med， controlled trial［J］. Neonatology，2020，117（4）：522-528
2004，36（6）：782-801 ［31］ CHANG E，BALLARD K E，JOHNSON P N，et al.
［20］HIRANI D，ALVIRA C M，DANOPOULOS S，et al. Mac⁃ Azithromycin for eradication of Ureaplasma and preven⁃
rophage⁃derived IL⁃6 trans⁃signalling as a novel target in tion of bronchopulmonary dysplasia in preterm neonates
the pathogenesis of bronchopulmonary dysplasia［J］. Eur⁃ in the neonatal intensive care unit［J］. J Pediatr Pharmacol
Respir J，2022，59（2）：2002248 Ther，2023，28（1）：10-19
［21］KALYMBETOVA T V，SELVAKUMAR B，RODRÍGUEZ⁃ ［32］BALLARD H O，BERNARD P，QUALLS J，et al. Azithro⁃
CASTILLO J A，et al. Resident alveolar macrophages are mycin protects against hyperoxic lung injury in neonatal
master regulators of arrested alveolarization in experimen⁃ rats［J］. J Investig Med，2007，55（6）：299-305
tal bronchopulmonary dysplasia［J］. J Pathol，2018，245 ［33］LONDHE V A，SUNDAR I K，LOPEZ B，et al. Hyperoxia
（2）：153-159 impairs alveolar formation and induces senescence
［22］HAYDAR D，CORY T J，BIRKET S E，et al. Azithromy⁃ through decreased histone deacetylase activity and up ⁃
cin polarizes macrophages to an M2 phenotype via inhibi⁃ regulation of p21 in neonatal mouse lung［J］. Pediatr Res，
tion of the STAT1 and NF⁃κB signaling pathways［J］. J 2011，69（5 Pt 1）：371-377
Immunol，2019，203（4）：1021-1030 ［收稿日期］ 2024-01-26
［23］OLIVER M E，HINKS T S C. Azithromycin in viral infec⁃ （本文编辑：戴王娟）